TD Cowen analyst Josh Jennings reiterated a Buy rating on TransMedics Group today and set a price target of $170.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors highlighting the strategic importance and growth potential of TransMedics Group. The recent acquisition of OrganOx by Terumo for $1.5 billion emphasizes the increasing value of organ preservation technologies, which are becoming a focal point for major MedTech companies involved in the transplant industry. This acquisition, along with previous similar transactions, indicates that organ transplantation is evolving into a significant growth market.
TransMedics is well-positioned to capitalize on this trend due to its unmatched Organ Care System (OCS) platform, which, along with its logistics capabilities, sets it apart from competitors. The company’s proven clinical track record and ability to significantly boost transplant volumes for adopters further reinforce its competitive edge. These factors collectively suggest that TransMedics is poised for growth, justifying the Buy rating.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Humacyte. According to TipRanks, Jennings has an average return of 1.6% and a 49.50% success rate on recommended stocks.
In another report released on August 22, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $135.00 price target.